Financial Performance
Lupin reported an operating revenue of ₹7,474.66 crore for the quarter ending March 31, 2026, representing a growth of 31.9% compared to the previous year. The bottom line saw a significant expansion with net profit for the quarter growing by 89% YoY to ₹1,460.34 crore. The full-year EBITDA margin reached 29.7%, driven by a favorable product mix in the US market and operational efficiencies.
Management noted that the growth was largely volume-led across both US and domestic segments, helping to offset low single-digit price erosion in the base generic portfolio.
Management Outlook
For FY27, management has provided a conservative guidance, projecting high single-digit revenue growth with EBITDA margins moderating to approximately 25%. This adjustment accounts for anticipated generic competition in high-margin US products such as Tolvaptan and Mirabegron. The company intends to launch over 50 products in the US over the next three years, focusing on respiratory, complex injectables, and biosimilars.
In the domestic market, Lupin aims to continue outperforming the Indian Pharmaceutical Market by 1.2 to 1.3 times, supported by a chronic-heavy portfolio and a field force of 12,000 personnel.
Business Overview
Lupin Limited is a leading Indian multinational pharmaceutical company focusing on generic formulations, complex generics, and biosimilars. The US remains its largest market, contributing $1.31 billion in FY26 sales, followed by India, where chronic therapies now account for 66% of the portfolio. The company recently expanded its European footprint through the acquisition of Vizuo Pharma, targeting the ophthalmology segment.
Furthermore, the company has secured key partnerships for biosimilar distribution, including a collaboration with Valorim for the US market.
Sector Dynamics
The global pharmaceutical landscape is transitioning toward complex generics as standard generic segments face persistent pricing pressure and regulatory scrutiny. Lupin's management highlighted that while price erosion in the US has stabilized at low single digits, the high-barrier entry of complex injectables provides a more sustainable margin profile. The company is also navigating macro headwinds, including increased air and ocean freight costs due to geopolitical tensions.
On the regulatory front, the receipt of an EIR for the Goa facility and VAI status for Pithampur Unit 2 reflects improved compliance across global manufacturing sites.
What to Watch
- Impact of competitive entries on Tolvaptan and Mirabegron margins in the US during FY27
- Execution of the Semaglutide launch in India and emerging markets planned for later this fiscal year
- Clinical progress and filing timelines for the biosimilar pipeline, including Pegfilgrastim and Ranibizumab
- Sustainability of the 25% EBITDA margin floor amidst rising freight costs and R&D investments
- The impact of the Vizuo Pharma integration on the European ophthalmology market share
Management Quote
This quarter marked our 15th consecutive quarter of year-over-year growth with highest ever sales and profitability.
